Entering text into the input field will update the search result below

Global Human Organoids Market - Know More About The Key Players

May 28, 2021 9:03 AM ET
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Summary

  • Growing focus on developing alternatives for animal testing models.
  • Significant increase in research funding and venture capital investments for the development of human organoids.
  • Growing initiatives to increase awareness about organoids.
  • Increasing focus on drug discovery activities.
  • Rising demand for organ transplantation.

Major Leaders of the Global Human Organoids Market:

BioIVT (US), Thermo Fisher Scientific (US), ZenBio (US), Corning (US), Organovo (US), Cyprio (France), Biopredic International (France), CELLINK (Sweden), Emulate (US), Hµrel Corporation (US), InSphero (Switzerland), Kerafast (US), Kirkstall (UK), and MIMETAS (Netherlands) are some of the major players in the human organoids market among others.

Growth Strategies Adopted By Them:

The analysis of market developments between 2017 and 2020 revealed that several growth strategies such as research collaborations were adopted by market players to strengthen their product portfolios and maintain a competitive position in the human orgnaoids market.

Some of the major end users of the company’s products are research organizations, pharmaceutical and biotechnological companies, medical device companies, and academic research institutes. BioIVT offers its products and services across North America, the Asia Pacific, Europe, and the Middle East & Africa. The company has two distributors in the Asia Pacific region, namely, Veritas Corporation (Japan) and Research Institute for Liver Diseases (Shanghai) Co., Ltd. (CHINA).

What the Market Looks Like?

The global human organoids market size is projected to reach USD 1,901 million by 2025 from USD 850 million in 2020, at a CAGR of 17.5% during the forecast period.

Download PDF Brochure @ Human Organoids Market

BioIVT was founded in 1981 and is headquartered in New York, US. The company is a leading global provider of biological specimens, including human tissues, cell products, blood, and other biofluids. The company provides a wide range of services, ranging from target and biomarker validation, phenotypic assays to characterize novel therapeutics, and clinical assay development to in vitro hepatic modeling solutions. It is a supplier of ADME-Tox model systems, including hepatocytes and subcellular fractions, to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and the effects on disease processes.

Thermo Fisher Scientific is engaged in the development, manufacturing, and marketing of analytical instruments, reagents and consumables, equipment, and software products. The company operates its businesses through four segments, namely, Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Services. The human liver model business comes under the Life Sciences Solutions segment. The company pursues both organic and inorganic growth strategies.

The company has a strong geographic presence in more than 50 countries across North America, Asia Pacific, Europe, and Latin America. Its major subsidiaries are Thermo Scientific Microbiology Sdn. Bhd (Malaysia), Thermo Scientific Microbiology Pte Ltd. (Singapore), Laboratory Management Systems, Inc. (US), Thermo Dutch Holdings Limited Partnership (UK), Thermo EGS Gauging LLC (US), Fisher Clinical Services Limited Liability Company (Russia), Fisher Clinical Services Japan K.K., and Thermo Fisher Scientific C.V. (Netherlands).

Get the Sample Pages@ Human Organoids Market

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.